Meldungen zum Thema Medizin

Thema abonnieren

Abonnieren Sie alle Meldungen zum Thema Medizin

21.02.2019 – 08:01
Primex Pharmaceuticals
Primex Pharmaceuticals and POA Pharma Sign a Strategic Partnership to Commercialise OZALIN in the Nordic Region
Gothenburg, Sweden and Zug, Switzerland (ots/PRNewswire) - POA Pharma Scandinavia AB, a market-oriented Boutique Healthcare Company, working in close contact with healthcare organizations, professionals and hospitals in Nordic countries and Primex Pharmaceuticals AG, an innovative Anaesthesia pharmaceutical company, ...
20.02.2019 – 19:02
Novasep
Novasep Announces the Success of Its Consent Solicitation Extending the Maturity of Its Notes
Lyon, France (ots/PRNewswire) - - All resolutions were approved by 100% of the participating Noteholders and C Warrantholders - Noteholders representing 99.9% of total outstanding principal amount participated Novasep Holding S.A.S ("Novasep"), a leading supplier of services and technologies for the life sciences industry, is pleased to announce that the consent ...
20.02.2019 – 15:54
Alvogen
Alvogen Launches Generic Equivalent to Suboxone® (Buprenorphine/Naloxone) Sublingual Film
Pine Brook, New Jersey (ots/PRNewswire) - Global pharmaceutical company, Alvogen, has launched its generic equivalent to Suboxone® sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S., which will be available in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg, and 12 mg/3mg strengths. The launch took ...
16.02.2019 – 23:10
Merck KGaA
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...
11.02.2019 – 23:55
Merck KGaA
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...
06.02.2019 – 15:01
Merck KGaA
Merck to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline
Darmstadt, Germany (ots/PRNewswire) - Not intended for US, Canada or UK-based media Merck to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline - Merck investing $70 million in U.S. Research & Development Hub - Expansion of R&D footprint to accelerate science and innovation in Oncology, ...
05.02.2019 – 14:15
CartiHeal (2009) Ltd.
CartiHeal Performs First Agili-C(TM) Cartilage Repair Implantation Procedures at Missouri Orthopaedic Institute
Kfar Saba, Israel (ots/PRNewswire) - Four patients enrolled and operated on by sports medicine surgeon Dr. Seth L. Sherman, MD Seth L. Sherman, MD, a sports medicine orthopaedic surgeon at Missouri Orthopaedic Institute, recently became one of the first American surgeons to enroll patients in a clinical research ...
05.02.2019 – 13:19
Merck KGaA
Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers
Darmstadt, Germany (ots/PRNewswire) - Not intended for US, Canada or UK-based media - Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers - Merck will receive an upfront payment of EUR300 million ...
31.01.2019 – 16:34
Novasep
Novasep Announces the Launch of a Consent Solicitation for the Maturity Extension of Notes with Requisite Voting Majority of the Noteholders Already Secured
Lyon, France (ots/PRNewswire) - Novasep Holding S.A.S ("Novasep"), a leading supplier of services and technologies for the life sciences industry, announces the launch of a consent solicitation (the "Consent Solicitation") in order to, inter alia : - extend the maturity of the senior notes in an initial aggregate ...
30.01.2019 – 08:12
ForaCare Suisse AG
2
ForaCare Suisse AG forms service-oriented partnership with B. Braun
29.01.2019 – 15:37
Kanabo Research
Lights Out for Insomnia: New Kanabo Research Study Offers Encouraging Results
Tel Aviv, Israel (ots/PRNewswire) - Kanabo Research is proud to present the promising results of its pre-clinical trial, which brings the company one step closer to providing a safe remedy for insomnia and other sleep disorders, without the risk of dependency or the possibility of an overdose. (Photo: ...
25.01.2019 – 15:32
Hovione
Hovione Issues $50 Million Bond
Lisbon (ots/PRNewswire) - Hovione has issued a bond of $50 million US dollars maturing in 2033. (Logo: https://mma.prnewswire.com/media/813604/Hovione_Logo.jpg ) The bond was arranged and subscribed by Banco BPI, S.A.. According to António Almeida, Hovione's CFO, "we issued this bond to strengthen our balance sheet as we embark in a new phase of significant capital expansion. We issued a USD denominated bond because the majority of our sales is in the USA". The bond is ...
25.01.2019 – 09:01
Zentiva
Zentiva Strengthens European Generic Footprint With Prague Manufacturing Site Investment
Prague (ots/PRNewswire) - Zentiva is investing EUR 30 million to maximize its manufacturing site capabilities in Prague. The investment further strengthens Zentiva's manufacturing footprint and is part of a broader ambition to become the champion of generics in Europe. (Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg ) Thomas Koene, Head of Industrial ...
24.01.2019 – 14:01
Merck KGaA
Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to both compounds in all other disease areas, including oncology - Merck retains the rights to utilize and ...
24.01.2019 – 08:01
Cannabis Europa
Cannabis Europa: France on Cusp of Major Breakthrough in Medical Cannabis Access
London (ots/PRNewswire) - - 8th February 2019: Industry leaders to meet at Cannabis Europa Paris for the first major industry conference in France - This follows recommendation by the French Medicines Agency (ANSM) in December 2019 to legalise medical cannabis use - France is seen as crucial market by the global medical cannabis industry for both the size of the ...
23.01.2019 – 16:01
Philogen
Philogen Announces Collaboration With Celgene
Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Celgene, to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Celgene, a leader in the discovery and development ...
23.01.2019 – 16:01
Philogen
Philogen Announces Collaboration
Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Novartis, a leader in the discovery and development of therapies for cancer patients," commented Dr. ...
23.01.2019 – 16:00
Philogen
Philogen Announces Drug Discovery Collaboration With Johnson & Johnson Innovation
Siena, Italy (ots/PRNewswire) - Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecule-based therapeutics utilizing Philochem's novel ...
14.01.2019 – 09:11
H&D Wireless AB
H&D Wireless Receives Order for Revolutionary EU Project for Osteoarthritis Treatment-order Value SEK 5.5 M
Stockholm (ots/PRNewswire) - Nasdaq First North - listed H&D Wireless AB has been selected as an IoT partner in a European research consortium that aims to greatly reduce the disease of osteoarthritis. H&D Wireless will contribute with the Internet of things (IoT) solution based on the company's proprietary Griffin ...
09.01.2019 – 10:00
Medasense Biometrics Ltd
Medasense Announces Compatibility with Philips IntelliVue Patient Monitors
Ramat Gan, Israel (ots/PRNewswire) - Medasense Biometrics Ltd., developer of the physiological pain-response monitoring technology (NOL® -- the Nociception Level Index), now supports Philips IntelliVue Patient Monitors for anesthesia and critical care monitoring. (Photo: https://mma.prnewswire.com/media/805789/Medasense_PMD_200_Monitor.jpg ) Commercially available in ...
07.01.2019 – 08:01
Daiichi Sankyo Europe GmbH
Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...
04.01.2019 – 06:01
Sophia Genetics
SOPHiA GENETICS Raises $77 Million to Accelerate the Democratization of Data-Driven Medicine
San Francisco (ots/PRNewswire) - SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco. Generation were joined by Idinvest ...
03.01.2019 – 11:43
ATAI Life Sciences
ATAI Life Sciences acquires majority stake in Perception Neuroscience to develop arketamine therapy for neuropsychiatric diseases
Munich and New York (ots) - ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry. Perception was founded by Jonathan Sporn, MD, and Jay Kranzler, MD, PhD, both of whom have held ...
03.01.2019 – 10:01
ProBioGen AG
ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals
Berlin (ots/PRNewswire) - Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus' grant of an exclusive license to ...
03.01.2019 – 08:01
NORGINE B.V. and KOREA PHARMA CO., LTD.
NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea
Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...
21.12.2018 – 20:02
Merck KGaA
Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...
20.12.2018 – 19:07
G&G Biotechnology BV
POLYTECH Health & Aesthetics GmbH - Quality Made in Germany Pays Off: CE Approval For Breast Implants From One of the International Leading Companies Currently Confirmed
Dieburg, Germany (ots/PRNewswire) - On December 18, 2018, POLYTECH sold the three millionth implant since its establishment in 1986. The company is the only German manufacturer and present in over 75 countries worldwide. All implants are manufactured in the company's own production facilities in Dieburg near ...

12345678910Nächste